Phenprocoumon and acenocoumarol treatment in paediatric patients

• References

• 1 Andrew M, Marzinotto V, Brooker LA. et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost 1994; 71: 265-269.
• 2 Bonduel M, Sciuccati G, Hepner M. et al. Acenocoumarol therapy in pediatric patients. J Thromb Haemost 2003; 1: 1740-1743.
• 3 Streif W, Andrew M, Marzinotto V. et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999; 94: 3007-3014.
• 4 Michelson AD, Bovill E, Monagle P. et al. Antithrombotic therapy in children. Chest 1998; 114 (Suppl. 05) 748S-769S.
• 5 Monagle P, Chalmers E, Chan A. et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 887S-8968S.
• 6 Biss TT, Avery PJ, Walsh PM. et al. Comparison of ’time within therapeutic INR range’ with ’percentage INR within therapeutic range’ for assessing long-term anticoagulation control in children. J Thromb Haemost 2011; 9: 1090-1092.
• 7 Hutten BA, Prins MH, Redekop WK. et al. Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists. Thromb Haemost 1999; 82: 1260-1263.
• 8 Rosendaal FR, Cannegieter SC, van der Meer FJ. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
• 9 Mitchell LG, Male C. Outcome measures in interventional trials for prevention or treatment of venous thrombosis in the pediatric population. Semin Thromb Hemost 2011; 37: 840-847.
• 10 Andrew M, Marzinotto V, Massicotte P. et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35: 78-83.
• 11 van Ommen CH, van den Dool EJ, Peters M. Nadroparin therapy in pediatric patients with venous thromboembolic disease. J Pediatr Hematol Oncol 2008; 30: 230-234.
• 12 Nowak-Gottl U, Dietrich K, Schaffranek D. et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 2010; 116: 6101-6105.
• 13 Biss TT, Avery PJ, Brandao LR. et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 2012; 119: 868-873.
• 14 Moreau C, Bajolle F, Siguret V. et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood 2012; 119: 861-867.
• 15 Gadisseur AP, Breukink-Engbers WG, van der Meer FJ. et al. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med 2003; 163: 2639-2646.
• 16 Laporte S, Quenet S, Buchmuller-Cordier A. et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost 2003; 89: 458-467.
• 17 Bauman ME, Black K, Kuhle S. et al. KIDCLOT: the importance of validated educational intervention for optimal long term warfarin management in children. Thromb Res 2009; 123: 707-709.
• 18 Bauman ME, Black K, Bauman ML. et al. EMPoWarMENT: Edmonton pediatric warfarin self-management pilot study in children with primarily cardiac disease. Thromb Res 2010; 126: e110-e115.
• 19 Bonduel MM. Oral anticoagulation therapy in children. Thromb Res 2006; 118: 85-94.
• 20 Christensen TD, Larsen TB, Hjortdal VE. Self-testing and self-management of oral anticoagulation therapy in children. Thromb Haemost 2011; 106: 391-397.